A Rational Approach to the Development of Drug Combinations in Thoracic Oncology

被引：0

作者：

Camidge, D. Ross ^{[1
,2
,3
]}

机构：

[1] Univ Colorado Anschutz Med Campus, Thorac Oncol, Denver, CO 80045 USA

[2] Univ Colorado Anschutz Med Campus, Div Med Oncol, Denver, CO 80045 USA

[3] Univ Colorado Anschutz Med Campus, Lung Canc Res, Denver, CO 80045 USA

来源：

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2019年 / 17卷 / 08期

关键词：

CELL LUNG-CANCER; OPEN-LABEL; PHASE-II; CHEMOTHERAPY; CARBOPLATIN; PACLITAXEL; TRIAL;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：430 / 432

页数：3

共 7 条

[1] A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients [J].

Byers, Lauren Averett ;

Horn, Leora ;

Ghandi, Jitendra ;

Kloecker, Goetz ;

Owonikoko, Taofeek ;

Waqar, Saiama Naheed ;

Krzakowski, Maciej ;

Cardnell, Robert J. ;

Fujimoto, Junya ;

Taverna, Pietro ;

Azab, Mohammad ;

Camidge, David Ross .

ONCOTARGET, 2017, 8 (46) :81441-81454

[2] A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer [J].

Camidge, D. Ross ;

Berge, Eamon M. ;

Doebele, Robert C. ;

Ballas, Marc S. ;

Jahan, Thierry ;

Haigentz, Missak, Jr. ;

Hoffman, David ;

Spicer, James ;

West, Howard ;

Lee, Pablo ;

Yang, Ling ;

Joshi, Adarsh ;

Gao, Ling ;

Yurasov, Sergey ;

Mita, Alain .

JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (10) :1532-1539

[3] Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma [J].

Camidge, D. Ross ;

Blais, Normand ;

Jonker, Derek J. ;

Soulieres, Denis ;

Doebele, Robert C. ;

Ruiz-Garcia, Ana ;

Thall, Aron ;

Zhang, Ke ;

Laurie, Scott A. ;

Chao, Richard C. ;

Chow, Laura Q. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) :307-319

[4] Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer [J].

Liu, Stephen V. ;

Camidge, D. Ross ;

Gettinger, Scott N. ;

Giaccone, Giuseppe ;

Heist, Rebecca S. ;

Hodi, F. Stephen ;

Ready, Neal E. ;

Zhang, Wei ;

Wallin, Jeffrey ;

Funke, Roel ;

Waterkamp, Daniel ;

Foster, Paul ;

Iizuka, Koho ;

Powderly, John .

EUROPEAN JOURNAL OF CANCER, 2018, 101 :114-122

[5] Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee [J].

Paller, Channing J. ;

Bradbury, Penelope A. ;

Ivy, S. Percy ;

Seymour, Lesley ;

LoRusso, Patricia M. ;

Baker, Laurence ;

Rubinstein, Larry ;

Huang, Erich ;

Collyar, Deborah ;

Groshen, Susan ;

Reeves, Steven ;

Ellis, Lee M. ;

Sargent, Daniel J. ;

Rosner, Gary L. ;

LeBlanc, Michael L. ;

Ratain, Mark J. .

CLINICAL CANCER RESEARCH, 2014, 20 (16) :4210-4217

[6] Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer [J].

von Pawel, Joachim ;

Harvey, Jimmie H. ;

Spigel, David R. ;

Dediu, Mircea ;

Reck, Martin ;

Cebotaru, Cristina L. ;

Humphreys, Robin C. ;

Gribbin, Matthew J. ;

Fox, Norma Lynn ;

Camidge, D. Ross .

CLINICAL LUNG CANCER, 2014, 15 (03) :188-+

[7]

York Emily R, 2017, J Thorac Oncol, V12, pe85, DOI 10.1016/j.jtho.2017.02.020

← 1 →